BNET Industries
Emergent Biosolutions (EBS) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $182.9M
- Profit
- Dec 31 2007
- $22.9M
- Market Cap
- Dec 02 2008
- $725.2M
Latest News and Analysis
Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the 6th Annual Southwestern Showcase Investor Conference scheduled for Thursday, November 20, 2008 at 1:40 pm Central. A member of the company's senior management team will provide a corporate overview, including a...
Emergent BioSolutions Files Universal Shelf Registration Statement
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has filed with the U.S. Securities and Exchange Commission SEC a universal shelf registration statement which, when declared effective, will permit the company to issue up to an aggregate of $100 million of common stock, preferred stock, debt securities...
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008
* 3Q and nine month 2008 total revenues increased 30 and 53 percent, respectively, over comparable prior year periods * 3Q 2008 net income of $10.4 million, or $0.35 per share, represents an increase of 265 percent over prior year * Nine month 2008 net income...
Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Rodman & Renshaw Annual Global Investment Conference scheduled for Wednesday, November 12, 2008 at 2:00 pm Eastern. A member of the company's senior management team will provide a corporate overview, including...
Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for the third quarter of 2008 on Thursday, November 6, 2008, after market close. Company management will host a conference call at 4:30 pm Eastern on November 6, 2008 to discuss these financial results, recent...
U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax® and Anthrax Immune Globulin under Prep Act
HHS Secretary Determines That Potential Threat of Exposure to Anthrax Constitutes a Public Health Emergency ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that two medical countermeasures included in its anthrax franchise -- BioThrax[R] Anthrax Vaccine Adsorbed and Anthrax Immune Globulin AIG -- have been included...
U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million
New Contract Extends USG's Commitment to Purchase BioThrax Through 3Q 2011 and is a Follow-on to the Existing 2007, $448 Million Contract ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health...
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
--AV7909 Contract is in Addition to Recently Announced $24 Million Development Contract for Anthrax Monoclonal and Pending Proposal to Supply HHS with Up to 25 Million Doses of a Recombinant Anthrax Vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with...
Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Department of Health and Human Services HHS has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine rPA is technically acceptable and within the competitive range. Emergent's proposal was in response to HHS's request...
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a contract from the Department of Health and Human Services HHS for over $24.3 million to fund the further development of Emergent's anthrax monoclonal antibody AVP-21D9. This contract will be jointly administered through the Office of the...
The Daily Record News Briefs: August 14, 2008
Emergent's lobbying tab Biopharmaceutical company Emergent BioSolutions Inc. spent $560,000 lobbying the federal government in the second quarter, according to a recent disclosure form. The Rockville-based company lobbied on appropriations and the government stockpiling of biodefense vaccines. Emergent holds a three-year, $448 million contract with the Department...
Emergent BioSolutions Reports Financial Results for Second Quarter 2008
-- Continued delivery of BioThrax[R] doses under current HHS contract drives 88 percent increase in Q2 2008 revenue over Q2 2007 -- Recent acquisitions expand anthrax franchise -- Financial outlook for 2008 is reaffirmed ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) announced today...
Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be presenting at the BMO Capital Markets "Focus on Healthcare Conference" on Wednesday August 6, 2008 at 11:15 AM Eastern. A member of the company's senior management team will provide a corporate overview, including a discussion of...
Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
The company's submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has submitted a proposal in response to a request for...
Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) issued the following statement in response to the announcement by Protein Sciences Corporation PSC that PSC is attempting to terminate its asset purchase agreement between the two companies: "The asset purchase agreement between Emergent BioSolutions and PSC has not been terminated....
Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the second quarter of 2008 on Thursday, August 7, 2008, before market open. Company management will host a conference call at 9:00 am Eastern on August 7, 2008 to discuss these financial...
Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine and Next Generation Anthrax Vaccine Candidates
The rBOT Grant is the First Government Award in Support of the Company's Botulinum Vaccine Program ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases NIAID to fund the...
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation
-- Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009 -- The vaccine candidate, MVA85A, has been granted orphan drug designation by the European Medicines Agency EMEA ...
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition
* Suit alleges fraud by PSC management and contract breaches by PSC * Emergent seeks immediate repayment of $10 million bridge loan secured by all of PSC's assets plus other relief ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated a lawsuit...
Rockville-based Emergent has upbeat quarter
Emergent BioSolutions Inc., of Rockville, maker of BioThrax, the only anthrax vaccine approved by federal regulators, posted a first- quarter profit on higher sales of the vaccine. Emergent reported first-quarter net income of $7.02 million, or 24 cents per diluted share, compared with a loss of $2.69 million, or 10...
- Next »
- page 1 of 1
- « Previous
- Incorporated: 1998
- CEO: Mr. Fuad El-Hibri
Emergent BioSolutions is a biopharmaceutical company that develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. At Dec 31 2007, Co. manufactured and marketed BioThrax®, a vaccine for the prevention of anthrax infection. Co. operates in two business segments: biodefense, which focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare; and commercial, which focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Emergent Biosolutions Company Info
Board of Directors
Mr. Fuad El-Hibri
Chairman
Dr. Zsolt Harsanyi Ph.D.
Dr. Louis W. Sullivan M.D
Mr. Joseph M. Allbaugh
Dr. Sue Bailey M.D.
Mr. Jerome M. Hauer
Mr. Ronald B. Richard
Dr. Shahzad Malik
Contact Information
2273 Research Blvd.
Suite 400
Rockville, MD
http://www.emergentbiosolutions.com
301 795-1800
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
